Skip to main content

THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia

Ziel

THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia.
THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management.
The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments.
Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2012-INNOVATION-1
Andere Projekte für diesen Aufruf anzeigen

Koordinator

UNIVERSITA DEGLI STUDI DI FERRARA
Adresse
Savonarola 9
44100 Ferrara
Italien
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 584 000
Kontakt Verwaltung
Roberto Gambari (Prof.)

Beteiligte (13)

KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIA
Zypern
EU-Beitrag
€ 440 000
Adresse
6 Iroon Avenue
2371 Agios Dometios
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Marios Flouros (Mr.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Niederlande
EU-Beitrag
€ 370 000
Adresse
Dr Molewaterplein 40
3015 GD Rotterdam
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Riet Zeijl (Mrs.)
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU-Beitrag
€ 370 000
Adresse
Soranou Efesiou 4
115 27 Athina
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Dimitris Raptis (Mr.)
CORNELL UNIVERSITY CORPORATION
Vereinigte Staaten
EU-Beitrag
€ 233 587,33
Adresse
Pine Tree Road 373
14853 Ithaca Ny
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Michelle Lewis (Ms.)
Masarykova univerzita
Tschechien
EU-Beitrag
€ 320 000
Adresse
Zerotinovo Namesti 9
601 77 Brno
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Petr Holub (Dr.)
UNIVERSITA DEGLI STUDI DI CAGLIARI
Italien
EU-Beitrag
€ 320 000
Adresse
Via Universita 40
09124 Cagliari
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Tiziana Cubeddu (Mrs.)
KING'S COLLEGE LONDON
United Kingdom
EU-Beitrag
€ 320 000
Adresse
Strand
WC2R 2LS London
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Paul Labbett (Mr.)
GENIKO LAIKO NOSOKOMEIO ATHINON*GENERAL HOSPITAL OF ATHENS LAIKO
Greece
EU-Beitrag
€ 320 000
Adresse
Agiou Thoma 17
11527 Athina
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Ersi Voskaridou (Dr.)
NOVAMECHANICS LIMITED
Zypern
EU-Beitrag
€ 620 477,53
Adresse
Digeni Akrita 51
1070 Nicosia
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Antreas Afantitis (Dr.)
BIOCEPS
Israel
EU-Beitrag
€ 97 761
Adresse
Ziv Medical Center, The Research Department, Harambam Street
1311001 Tzfat
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Eitan Fibach (Prof.)
HARBOUR ANTIBODIES BV
Niederlande
EU-Beitrag
€ 100 000
Adresse
Stationsplein 45, A4.004
3013 AK Rotterdam
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Riet Van Zeijl (Ms.)
IRBM SCIENCE PARK SPA
Italien
EU-Beitrag
€ 787 761,47
Adresse
Via Pontina Km 30600
00040 Pomezia Rm
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Ilaria Iannaccone (Dr.)
THE CHILDREN'S HOSPITAL OF PHILADELPHIA NON PROFIT ORG
Vereinigte Staaten
EU-Beitrag
€ 136 412,67
Adresse
Civic Center Blvd
19104 Philadelphia
Aktivitätstyp
Other
Kontakt Verwaltung
Robert Denight (Mr.)